Sanofi Puts Faith In Rare Review Procedure For ‘Breakthrough’ Sleeping Sickness Drug
Sanofi believes its fully oral sleeping sickness treatment, fexinidazole, will support efforts to eliminate the disease by 2020. The European Medicines Agency is set to start reviewing the product soon with a view to it being used in Africa.
You may also be interested in...
CTI BioPharma has had a bumpy ride with pacrotinib, its investigational treatment for patients with myelofibrosis who have thrombocytopenia. But it has persevered and should learn this week whether the European Medicines Agency will recommend that the product be approved for the sale across the EU. Pacritinib, J&J's apalutamide, and AEterna Zentaris's macimorelin are among a handful of products reaching the end of the approval process.
Sanofi has succeeded in its bid for a fast-track EU review of a drug that it believes could bring the goal of eradicating sleeping sickness closer.
In contrast with the five COVID-19 vaccines that are approved in the EU under conditional marketing authorizations, the European Medicines Agency has recommended that Valneva’s vaccine receive a standard approval.